CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Complexity of Selling Orally Inhaled and Nasal Drug Product CDMO Services

Selling Contract Development and Manufacturing Organisation (CDMO) services is a complex task that demands a versatile skill set, encompassing drug development expertise, technical and analytical knowledge in drug product manufacturing, equipment familiarity, and overall selling skills. Drug-device combination products bring an additional layer of complexity due to the variety of devices, intricate supply chains, and additional manufacturing processes for filling and assembly. This complexity is heightened in inhalation (nasal/pulmonary) product development, where device variability and rigorous analytical testing are significant challenges. This article explores the intricacies of selling these services and highlights the essential attributes of an exceptional business development professional.

The CDMO industry, as we know today, largely started in the late 1990s driven by multiple factors, amongst these the selling of excess manufacturing facilities by global pharmaceutical companies as older products went off patent.¹ The greatest growth driver, however, was the explosion of early-stage bio/pharma companies, thanks to the maturity of biotechnology and the availability of external funding.¹ Due to the cost of establishing owned manufacturing facilities, these emerging biopharma companies (EBPs) fuelled the CDMO industry by outsourcing all or part of their product development and/or manufacturing requirements.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026